跳至主要内容
临床试验/ACTRN12617000087358
ACTRN12617000087358进行中(未招募)3 期

Treatment optimisation trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.

niversity of Cologne0 个研究点目标入组 1,585 人开始时间: 2017年1月16日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
1,585

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 75 Years(—)
性别
All

入选标准

  • Histologically proven classical Hodgkin lymphoma;
  • - First diagnosis, no previous treatment
  • - Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV.
  • - Main cohort: 18 to 60 years of age;
  • - Older cohort: 61 - 75 years of age.

排除标准

  • - Composite lymphoma or nodular lymphocyte predominant Hodgkin lymphoma;
  • - Previous malignancy (exceptions: basalioma, carcinoma in situ of the cervic uteri, completely resected melanoma TNMpT1);
  • - Prior chemotherapy or radiotherapy;
  • - Concurrent disease which precludes protocol treatment;
  • - Pregnancy, lactation;
  • - Non-compliance.

研究者

发起方
niversity of Cologne

相似试验

已完成
不适用
Exploratory clinical study of first-line treatment for patients with advanced EGFR mutation-positive non-squamous non-small-cell lung canceradvanced EGFR mutation-positive non-squamous non-small cell lung cancer
JPRN-UMIN000015414Department of Thoracic Oncology Osaka Medical Center for Cardiovascular diseases40
进行中(未招募)
不适用
Pilotstudie zur Therapieoptimierungsstudie für den Morbus Hodgkin bei Kindern und JugendlichenPrüfung der Verträglichkeit der ChemotherapiekombinationVECOPA bei Patienten der Therapiegruppen 2 und 3 - GPOH-HD 2002 Pilot / VECOPAPilotstudie zur Therapieoptimierungsstudie für den Morbus Hodgkin bei Kindern und JugendlichenPrüfung der Verträglichkeit der ChemotherapiekombinationVECOPA bei Patienten der Therapiegruppen 2 und 3
EUCTR2004-005244-28-DEniversität Leipzig30
进行中(未招募)
不适用
Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients after primary orthotopic heart transplantation - Heart Cam & TamTherapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients after primary orthotopic heart transplantation.
EUCTR2006-005275-18-DEAstellas10
已完成
4 期
Therapeutic Efficacy Study (TES) For First Line of Antimalaria Drug (Dihydroartemisinin Piperaquine/DHP) in Two Sentinel Sites in Indonesia
ACTRN12622000248763World Health Organization, Country Office Indonesia142
已完成
Unknown
Controlled Clinical Therapy Pilot Study for the treatment of depression and anxiety in the context of post-acute cardiac and neurological rehabilitatioF32.1Moderate depressive episode
DRKS00033049Rehazentrum Oldenburg68